The global organ-on-a-chip market has been gaining significant traction in the past few years owing to the growing demand for alternative methods for drug screening and toxicity testing. organ-on-a-chip devices aim to mimic the physiological responses of human organs by replicating their complex microenvironment using microfabrication and microfluidic technologies. They incorporate living cells on a chip lined with microchannels and are capable of modelling organ-level functions and responses. Such devices are being seen as crucial tools for developing safe and effective drugs in a cost-effective manner while reducing dependence on animal testing. With technological advancements, the organ-on-a-chip technology is expected witness wider adoption across various industries in the coming years.
Market Dynamics:
The global organ-on-a-chip market is primarily driven by the rising drug development costs and limited success of new drug entities. Organ-on-a-chips provide human-body-on-a-chip platforms for testing drugs and chemical compounds, thus helping drug makers reduce failure rates and curb R&D expenditure. Moreover, stringent regulations regarding safety and efficacy of drugs along with growing emphasis on the 3Rs (Replacement, Reduction, and Refinement) in animal testing is positively influencing the adoption of organ-chip technology. However, the high costs associated with the development of organ-on-a-chip devices and lack of standardized procedures for validation of test results are some of the factors hindering the market growth. Meanwhile, growing funding from private and government bodies for organ chip research is creating new opportunities for market players.
Key Features of the Study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook